IHS Chemical Week

Chemical Week Magazine :: Newsbriefs

DSM Buys Stake in Antibody Firm

10:53 AM MDT | March 18, 2008 | Chemical Week Editorial Staff

DSM Venturing, the venture capital arm of DSM, says it has made an equity investment in biotech firm IQ Therapeutics (Groningen, the Netherlands), a developer of antibodies for vaccines. DSM says it holds a“significant minority share in the business,” although financial terms were not disclosed. IQ Therapeutics’ portfolio includes an anti-anthrax vaccine, a product with “great potential,” says Karen King, president, DSM...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis from the entire global chemical enterprise on chemweek.com
  • Mobile edition of Chemical Week
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional focus
  • Global outlook issue




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa